1. Eroom’s Law, the $2.6 Billion Problem, and Why Traditional R&D Has Stopped Working Jack Scannell named Eroom’s Law in […]

Executive Summary The global generic drug market sits at an unusual intersection: structural demand that will not shrink, a near-term

The generic pharmaceutical industry has a problem it created for itself. For decades, the dominant growth strategy was volume: file

There is a rule in corporate strategy that says any resource your competitor needs, and that you control, is a

Top-Level Key Takeaways 1. What the Rule of Three Actually Is (and What It Isn’t) 1.1 The Economic Premise The

1. Why the Generic Market Runs on Partnerships, Not Margins Generics and biosimilars filled 90% of all U.S. prescriptions dispensed

Executive Framing: The Cost Problem That Waste Built {#executive-framing} Generic drugs fill roughly nine out of every ten prescriptions dispensed

Section 1: The Modern API Manufacturing Landscape 1.1 What an API Is, and Why Its Manufacturing Process Is a Core

I. Executive Summary Key Takeaways The global CDMO market is on track to reach $465 billion by 2032, driven by